US 5,629,327 AGranted

Methods and compositions for inhibition of angiogenesis

AssigneeChildren's Hospital Medical Center

InventorRobert D'Amato

Life of this patent

Estimating the term…

Abstract

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

Claims3

Dependent claims

A method of treating undesired angiogenesis in a human or animal comprising, administering to the human or animal with the undesired angiogenesis a composition comprising an angiogenesis-inhibiting amount of thalidomide.

Dependencies are inferred from the claim text.

Facts

Application: 08/168,817Filed 15 Dec 1993 · continuation in part
Priority: 1 Mar 1993
Granted: 13 May 1997
Term ends: Not estimatedThe source records don’t support an estimate.

Classification42 codes

C07D 403/02
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group…
A61K 31/19
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids: carboxylic acids, e.g. valproic acid
A61K 31/40
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with one nitrogen as the only ring hetero atom,…
A61K 31/4035
Condensed with carbocyclic rings, e.g. carbazole: isoindoles, e.g. phthalimide

Family

Serial25,046Parent of this continuation-in-part · filed 1 Mar 1993
US 5,629,327 AThis patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results